Alternative Anticoagulation Management Strategies for the Patient With Heparin-Induced Thrombocytopenia Undergoing Cardiac Surgery

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 21, Issue 1, 2007, Pages 113-126

  Murphy, Glenn S ^a   Marymont, Jesse H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

argatroban; bivalirudin; cardiac surgical procedures; danaparoid; heparin induced thrombocytopenia; lepirudin

Indexed keywords

ANCROD; ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; DANAPAROID; HEPARIN; HIRULOG; ILOPROST; IMMUNOGLOBULIN G; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROSTACYCLIN; PROTAMINE; THROMBIN; THROMBOCYTE FACTOR 4; TIROFIBAN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL PROTOCOL; CONTINUOUS INFUSION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; HEART SURGERY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOTENSION; LOADING DRUG DOSE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SYSTEMATIC REVIEW; THROMBOSIS;

ANCROD; ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CHONDROITIN SULFATES; DERMATAN SULFATE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPARITIN SULFATE; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 33846707261     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2006.08.011     Document Type: Review

References (96)

1. Suh J.S., Aster R.H., and Visentin G.P. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin platelet factor 4. Blood 91 (1998) 916-922
2. Warkentin T.E., Hayward C.P., Boshkov L.K., et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84 (1994) 3691-3699
3. Warkentin T.E., and Greinacher A. Heparin-Induced Thrombocytopenia. (ed 3). (2004), Marcel Dekker, Inc, New York, NY 11-12
4. Warkentin T.E. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-Induced Thrombocytopenia. (ed 3). (2004), Marcel Dekker, Inc, New York, NY 59-60
5. Warkentin T.E., and Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 76 (2003) 2121-2131
6. Trossaert M., Gaillard A., Commin P.L., et al. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 101 (1998) 653-655
7. Bauer T.L., Arepally G., Konkle B.A., et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 95 (1997) 1242-1246
8. Warkentin T.E., Sheppard J.I., Horsewood P., et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96 (2000) 1703-1708
9. Walls J.T., Curtis J.J., Silver D., et al. Heparin-induced thrombocytopenia in open heart surgical patients: Sequelae of late recognition. Ann Thorac Surg 53 (1992) 787-791
10. Glock Y., Szmil E., Boudjema B., et al. Cardiovascular surgery and heparin-induced thrombocytopenia. Int Angiol 7 (1988) 238-245
11. Walls J.T., Boley T.M., Curtis J.J., et al. Heparin-induced thrombocytopenia in patients undergoing intra-aortic balloon pumping after open heart surgery. ASAIO J 38 (1992) 574-576
12. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 (1995) 1330-1335
13. Ramakrishna R., Manoharan A., Kwan Y.L., et al. Heparin-induced thrombocytopenia: Cross-reactivity between standard heparin, low-molecular-weight heparin, dalteparin (Fragmin), and heparinoid, danaparoid (Orgaran). Br J Haematol 91 (1995) 736-738
14. Greinacher A., Feigl M., and Muewller-Eckhardt C. Cross-reactivity studies between sera of patients with heparin-induced thrombocytopenia and a new low-molecular-weight heparin, reviparin. Thromb Haemost 72 (1994) 644-645
15. Horellou M.H., Conrad J., Lecrubier C., et al. Persistent heparin-induced thrombocytopenia despite therapy with low-molecular-weight heparin. Thromb Haemost 51 (1984) 134
16. Leroy J., Leclerc M.H., Delahousse B., et al. Treatment of heparin-associated thrombocytopenia and thrombosis with low-molecular-weight heparin. Semin Thromb Hemost 11 (1985) 326-329
17. Robitaille D., Leclerc J.R., Laberge R., et al. Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J Thorac Cardiovasc Surg 103 (1992) 597-599
18. Frederiksen J.W. Cardiopulmonary bypass in humans: bypassing unfractionated heparin. Ann Thorac Surg 70 (2000) 1434-1443
19. Warkentin T.E., Greinacher A., and The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Heparin-induced thrombocytopenia: Recognition, treatment, and prevention. Chest 126 (2004) 311S-337S
20. O-Yurvati A.H., Laub G.W., Southgate T.J., et al. Heparinless cardiopulmonary bypass with ancrod. Ann Thorac Surg 57 (1994) 1656-1658
21. Teasdale S.J., Zulys V.J., Mycyk T., et al. Ancrod anticoagulation for cardiopulmonary bypass in heparin-induced thrombocytopenia and thrombosis. Ann Thorac Surg 48 (1989) 712-713
22. Zulys V.J., Teasdale S.J., Michel E.R., et al. Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology 71 (1989) 870-877
23. Swan S.K., and Hursting M.J. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20 (2000) 318-329
24. Furukawa K., Ohteki H., Hirahara K., et al. The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations. J Thorac Cardiovasc Surg 122 (2001) 1255-1256
25. Edwards J.T., Hambly J.K., and Worrall N.K. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: Heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 75 (2003) 1622-1624
26. Cannon M.A., Butterworth J., Riley R.D., et al. Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery. Ann Thorac Surg 77 (2004) 711-713
27. Kieta D.R., McCammon A.T., Holman W.L., et al. Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation. Anesth Analg 96 (2003) 956-958
28. Meuleman D.G., Hobbelen P.M.J., Van Dedem G., et al. A novel antithrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: A survey of pharmacological properties in experimental animal models. Thromb Res 27 (1982) 353-363
29. Bradbrook I.D., Magnani H.N., Moelker H.C.T., et al. Org 10172: A low-molecular-weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol 23 (1987) 667-675
30. Newman P.M., Swansson R.L., and Chong B.H. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low-molecular-weight heparin and heparinoid. Thromb Haemost 80 (1998) 292-297
31. Doherty D.C., Ortel T.L., De Bruijn N., et al. "Heparin-free" cardiopulmonary bypass: First reported use of heparinoid (ORG 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology 73 (1990) 562-565
32. Gillis S., Merin G., Zahger D., et al. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia. Br J Haematol 98 (1997) 657-659
33. Magnani H.N., Beijering R.J.R., ten Cate J.W., et al. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: Pifarre R. (Ed). New Anticoagulants for the Cardiovascular Patient (1997), Hanley & Belfus, Philadelphia, PA 487-500
34. Grocott H.P., Root J., Berkowitz S.D., et al. Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium. J Cardiothorac Vasc Anesth 11 (1997) 875-877
35. Olin D.A., Urdaneta F., and Lobato E.B. Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth 14 (2000) 707-709
36. Gitlin S.D., Deeb G.M., and Yann C. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations. J Vasc Surg 27 (1998) 568-575
37. Poetzsch B., and Madlener K. Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-Induced Thrombocytopenia. (ed 3). (2004), Marcel Dekker, Inc, New York, NY 531-551
38. Carrier M., Robitaille D., Perrault L.P., et al. Heparin versus danaparoid in off-pump coronary bypass grafting: Results of a prospective randomized clinical trial. J Thorac Cardiovasc Surg 125 (2003) 325-329
39. Weitz J.I., Leslie B., and Hudoba M. Thrombin binds to soluble fibrin degradation products where it is prothrombosed from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 97 (1998) 544-552
40. Greinacher A. Lepirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-Induced Thrombocytopenia. (ed 3). (2004), Marcel Dekker, Inc, New York, NY 397-436
41. Wittkowsky A.K., and Kondo L.M. Lepirudin dosing in dialysis-dependent renal failure. Pharmacotherapy 20 (2000) 1123-1128
42. Koster A., Merkle F., Hansen R., et al. Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: Assessment of different filter systems. Anesth Analg 91 (2000) 265-269
43. Nuttall G.A., Oliver W.C., Santrach P.J., et al. Patients with a history of type II heparin-induced thrombocytopenia requiring cardiac surgery with cardiopulmonary bypass: A prospective observational case series. Anesth Analg 96 (2003) 344-350
44. Potzsch B., Madlener K., Seelig C., et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass-Assessment of whole-blood ecarin clotting time. Thromb Haemost 77 (1997) 920-925
45. Despotis G.J., Hogue C.W., Saleem R., et al. The relationship between hirudin and activated clotting time: Implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery. Anesth Analg 93 (2001) 28-32
46. Jabr K., Johnson J.H., McDonald M.H., et al. Plasma-modified ACT can be used to monitor bivalirudin (Angiomax) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia. J Extra Corpor Technol 36 (2004) 174-177
47. Measday M.A., Zucker M.L., Pan C.M., et al. Optimizing management of hirudin anticoagulation. J Extra Corpor Technol 37 (2005) 66-70
48. Pivalizza E.G. Monitoring of hirudin therapy with the thrombelastograph. J Clin Anesth 14 (2002) 456-458
49. Walenga J.M., Bakhos M., Messmore H.L., et al. Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model. Ann Thorac Surg 51 (1991) 271-277
50. Riess F.C., Lower C., Seeling C., et al. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man. J Thorac Cardiovasc Surg 110 (1995) 265-267
51. Koster A., Hansen R., Kuppe H., et al. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: A 1-year experience in 57 patients. J Cardiothorac Vasc Anesth 14 (2000) 243-248
52. Koster A., Pasic M., Bauer M., et al. Hirudin as anticoagulant for cardiopulmonary bypass: Importance of preoperative renal function. Ann Thorac Surg 69 (2000) 37-41
53. Manikappa S., Benfield K., Gan T.E., et al. Heparin-induced thrombocytopenia and the use of r-hirudin during cardiopulmonary bypass. Anaesth Intensive Care 33 (2005) 388-392
54. Latham P., Revelis A.F., Joshi G.P., et al. Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass. Anesthesiology 92 (2000) 263-267
55. Liu H., Fleming N.W., and Moore P.G. Anticoagulation for patients with heparin-induced thrombocytopenia using recombinant hirudin during cardiopulmonary bypass. J Clin Anesth 14 (2002) 452-455
56. Riess F.C., Potzsch B., Bader K., et al. A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery. Eur J Cardiothorac Surg 10 (1996) 386-388
57. Iqbal O., Tobu M., Aziz S., et al. Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization. J Card Surg 20 (2005) 42-51
58. Carr C.S., Rayner A., Ponte J., et al. Off-pump coronary artery bypass grafting in a heparin-induced thrombocytopenia type II patient using hirudin. Ann Thorac Surg 79 (2005) 696-698
59. Jormalainen M., Vento A.E., Wartiovaara-Kautto U., et al. Recombinant hirudin enhances cardiac output and decreases systemic vascular resistance during reperfusion after cardiopulmonary bypass in a porcine model. J Thorac Cardiovasc Surg 128 (2004) 189-196
60. Greinacher A., Eichler P., and Lubenow N. Anaphylactic reactions associated with lepirudin in patients with heparin-induced thrombocytopenia (HIT). Circulation 108 (2003) 2062-2065
61. Bartholomew J.R. Bivalirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-Induced Thrombocytopenia. (ed 3). (2004), Marcel Dekker, Inc, New York, NY 475-507
62. Fox I., Dawson A., Loynds P., et al. Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans. Thromb Hemost 69 (1993) 157-163
63. Robson R., White H., Aylward P., et al. Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose, and gender. Clin Pharmacol Ther 71 (2002) 433-439
64. Koster A., Chew D., Grundel M., et al. An assessment of different filter systems for extracorporeal elimination of bivalirudin: An in vitro study. Anesth Analg 96 (2003) 1316-1319
65. Stratmann G., deSilva A.M., Tseng E.E., et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg 98 (2004) 1635-1639
66. Lidon R.M., Theroux P., Juneau M., et al. Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects. Circulation 88 (1993) 1495-1501
67. Bittl J.A., Strony J., Brinker J.A., et al., Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 333 (1995) 764-769
68. Topol E.J., Bonan R., Jewitt D., et al. Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty. Circulation 87 (1993) 1622-1629
69. Casserly I.P., Kereiakes D.J., Grey W.A., et al. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. Thromb Res 113 (2004) 115-121
70. Merry A.F., Raudkivi P.J., Middleton N.G., et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 77 (2004) 925-931
71. Davis Z., Anderson R., Short D., et al. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann Thorac Surg 75 (2003) 264-265
72. Koster A., Chew D., Grundel M., et al. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg 96 (2003) 383-386
73. Spiess B.D., DeAnda A., McCarthy A., et al. Off-pump CABG in a patient with HITT anticoagulated with bivalirudin: A case report. Anesth Analg 93 (2002) SCA 70, (abstr)
74. Vasquez J.C., Vichiendilokkul A., Mahmood S., et al. Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. Ann Thorac Surg 74 (2002) 2177-2179
75. Clayton S.B., Acsell J.R., Crumbley A.J., et al. Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia. Ann Thorac Surg 78 (2004) 2167-2169
76. Koster A., Spiess B., Chew D.P., et al. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol 93 (2004) 356-359
77. Koster A., Yeter R., Buz S., et al. Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin: Results of a pilot study. J Thorac Cardiovasc Surg 129 (2005) 1391-1394
78. Bott J.N., Reddy K., and Krick S. Bivalirudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia. Ann Thorac Surg 76 (2003) 273-275
79. Smedira N.G., Dyke C.M., Koster A., et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 131 (2006) 686-692
80. Dyke C.M., Smedira N.G., Koster A., et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON study. J Thorac Cardiovasc Surg 131 (2006) 533-539
81. Olinger G.N., Hussey C.V., Olive J.A., et al. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation. J Thorac Cardiovasc Surg 87 (1984) 673-677
82. Addonizio V.P., Fisher C.A., Kappa J.R., et al. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost. Surgery 102 (1987) 796-807
83. Kappa J.R., Horn D., McIntosh C.L., et al. Iloprost (ZK36374), a new prostacyclin analogue, permits open cardiac surgery in patients with heparin-induced thrombocytopenia. Surg Forum 36 (1985) 285-286
84. Palmer Smith J., Walls J.T., Muscato M.S., et al. Extracorporeal circulation in a patient with heparin-induced thrombocytopenia. Anesthesiology 62 (1985) 363-365
85. Antoniou T., Kapetanakis E.I., Theodoraki K., et al. Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost. Heart Surg Forum 5 (2002) 354-357
86. Kappa J.R., Fisher C.A., Todd B., et al. Intraoperative management of patients with heparin-induced thrombocytopenia. Ann Thorac Surg 49 (1990) 714-722
87. Aouifi A., Blanc P., Piriou V., et al. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia. Ann Thorac Surg 71 (2001) 678-683
88. Mertzlufft F., Kuppe H., and Koster A. Management of urgent high-risk cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and coexisting disorders of renal function: Use of heparin and epoprostenol combined with on-line monitoring of platelet function. J Cardiothorac Vasc Anesth 14 (2000) 304-308
89. Koster A., Kukucka M., Bach F., et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb/IIIa antagonist tirofiban. Anesthesiology 94 (2001) 245-251
90. Koster A., Meyer O., Fischer T., et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. J Thorac Cardiovasc Surg 122 (2001) 1254-1255
91. Greinacher A., and Warkentin T.E. Treatment of heparin-induced thrombocytopenia: An overview. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-Induced Thrombocytopenia. (ed 3). (2004), Marcel Dekker, Inc, New York, NY 335-370
92. Warkentin T.E., and Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344 (2001) 1286-1292
93. Lubenow N., Kempf R., Eichner A., et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 122 (2002) 37-42
94. Olinger G.N., Hussey C.V., Olive J.A., et al. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation. J Thorac Cardiovasc Surg 87 (1984) 673-677
95. Potzsch B., Klovekorn W.P., and Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 343 (2000) 515
96. Lubenow N., Selling S., Wollert H.G., et al. Heparin-induced thrombocytopenia and cardiopulmonary bypass: Perioperative argatroban use. Ann Thorac Surg 75 (2003) 577-579